Profound Medical Corp
TSX:PRN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Cosco Shipping International (Hongkong) Co Ltd
HKEX:517
|
HK |
Profound Medical Corp
Income from Continuing Operations
Profound Medical Corp
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Profound Medical Corp
TSX:PRN
|
Income from Continuing Operations
-$42.6m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-13%
|
|
|
Theralase Technologies Inc
XTSX:TLT
|
Income from Continuing Operations
-CA$4.4m
|
CAGR 3-Years
8%
|
CAGR 5-Years
11%
|
CAGR 10-Years
2%
|
|
|
MedMira Inc
XTSX:MIR
|
Income from Continuing Operations
-CA$3.5m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-1%
|
|
|
Aurora Spine Corp
XTSX:ASG
|
Income from Continuing Operations
-$1.3m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
12%
|
|
|
O
|
Ondine Biomedical Inc
LSE:OBI
|
Income from Continuing Operations
-CA$19.1m
|
CAGR 3-Years
27%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Conavi Medical Corp
XTSX:CNVI
|
Income from Continuing Operations
-$16.2m
|
CAGR 3-Years
35%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
Profound Medical Corp
Glance View
Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
See Also
What is Profound Medical Corp's Income from Continuing Operations?
Income from Continuing Operations
-42.6m
USD
Based on the financial report for Dec 31, 2025, Profound Medical Corp's Income from Continuing Operations amounts to -42.6m USD.
What is Profound Medical Corp's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-13%
Over the last year, the Income from Continuing Operations growth was -53%. The average annual Income from Continuing Operations growth rates for Profound Medical Corp have been -14% over the past three years , -15% over the past five years , and -13% over the past ten years .
